Onco Actu du 10 mai 2019

	3.5 PRÉVENTION - UV
Sunscreen Ingredients Absorbed into Blood: Study [The Scientist] FDA researchers report that multiple active ingredients wind up in users’ bloodstream and recommend toxicology testing to investigate the clinical significance of the findings.
	4.1 DÉP., DIAG. & PRONO. - PROSTATE
Prostate cancer MRI scans: is the NHS ready? [Cancer Research UK] While it’s the most budget-friendly method to help assess if someone has prostate cancer, the latest guidelines could have a big impact on another NHS resource: its staff.
Prostate cancer: diagnosis and management [NICE] This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
Men with low risk prostate cancer must be offered option to 'watch and wait' instead of gruelling treatment [The Telegraph] For the first time, the official advice from the National Institute for Health and Care Excellence (Nice) says there is no survival benefit to having treatment, in cases identified as low risk.
	4.12 BIOPSIES LIQUIDES
Hong Kong's Take2 to Commercialize Early Cancer Detection Test; Focus on Healthcare Informatics [Genome Web] This second-generation version of the test uses a cell-free DNA sequencing strategy that targets the Epstein Barr virus.
Circulating Tumor DNA Forecasts Recurrence in Non-Metastatic Colorectal Cancer [Genome Web] Two independent research teams have found clues that circulating tumor DNA (ctDNA) can offer clinically useful insights into colorectal cancers (CRC) that have not progressed to metastasis.
Liquid Biopsy of Melanoma Surgery Drainage Fluid Shows Promise for Recurrence Monitoring [Genome Web] The team also believes that their seroma drainage method could be useful in other tumor types, where lymphadenectomy is common, and hope to extend the research into other areas like breast cancer.
	4.9 DÉP., DIAG. & PRONO. - SEIN
Research Brief: Women perceive the potential benefits of mammograms to be more important than the potential harms [University of Minnesota] In a study recently published in the journal Preventive Medicine, University of Minnesota researchers surveyed 557 U.S. women aged 30-59 regarding their views on mammograms.
	5. TRAITEMENTS
Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests [NCI] She cautioned, however, that the study was small and that the findings apply only to the care of patients with tumors that surgeons can safely remove at diagnosis. Patients are not candidates for the reduced amount of chemotherapy if their tumors are advanced or have spread to other parts of the body.
The Latest on Drug Failure and Approval Rates [In The Pipeline] As for breakdown by therapeutic area, CNS and cardiovascular drugs are at the bottom of the probability of success list at Phase III, followed by musculoskeletal and oncology drugs.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Preclinical data on MD Anderson Cancer Center-developed drug offers hope for Imbruvica-resistant mantle cell lymphoma patients [EndPoints] After isolating tumor cells from the cerebrospinal fluid from a patient who did not respond to multiple therapies including Imbruvica, MD Anderson Cancer Center scientists developed an Imbruvica-resistant B-cell lymphoma mouse model to test the therapeutic potential of their drug, IACS-10759.
	5.12.4 IMMUNOTHÉRAPIES - ESSAIS
Bristol-Myers' Opdivo fails in Phase 3 glioblastoma test [Biopharma Dive] Glioblastoma differs from other cancers in that therapies must get across the blood-brain barrier, designed to protect the brain from toxins. Scientists are just beginning to understand how immunotherapies do their work in the brain, according to the National Cancer Institute.
Bristol-Myers Squibb Announces Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo (nivolumab) Plus Radiation in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme [BMS] Opdivo is also being studied in patients with newly diagnosed MGMT-methylated GBM in the Phase 3 CheckMate -548 (NCT02667587) study, in which Opdivo is added to the current standard of care, radiation plus temozolomide.
Another PhIII #fail for Bristol-Myers’ star drug raises fresh questions about their R&D strategy as Merck surges further ahead [EndPoints] As usual, researchers will hold back the data for a future conference, but CheckMate-498 is another write-off.
Bristol-Myers' Opdivo fails late-stage brain cancer trial [Reuters] Opdivo, used in combination with radiation therapy, failed to extend survival in patients with glioblastoma multiforme (GBM), when compared with the chemotherapy temozolomide and radiation therapy.
	5.2 PHARMA
Servier's US push takes shape as Boston HQ opens [Biopharma Dive] Like the rest of the industry, Servier hopes to become a larger player in the fast-growing oncology market. The deal with Shire gave it rights to two older cancer drugs and a then-experimental, now-approved leukemia treatment called Asparlas (calaspargase pegol).
	5.2.1 PHARMA - PARTENARIATS
Spectrum bags cancer drugs, interferon platform from ImmunGene [Fierce Biotech] University of California, Los Angeles scientists developed the platform, dubbed FIT, to fuse interferon with antibodies against tumor antigens. Interferon was hailed as a cancer breakthrough in the 1970s, only for systemic toxicity to restrict it to a marginal role in treating the disease.
	5.2.3 PHARMA - ÉCONOMIE
Novartis sees Saudi Arabia as promising market for producing its cancer drugs [Fierce Pharma] Officials told the publication that Novartis had decided to produce its oncology drugs in Saudi Arabia, a country that reports cancer rates above world averages. It will find plenty of competition from other Western drugmakers that got there first.
	5.4 TRAITEMENTS - ECONOMIE
Cancer patients should be treated by their doctors, not pharmacy benefit managers [STAT] Pharmacy benefit managers were supposed to help bring down the cost of drugs by negotiating with competing drug companies and by “encouraging consumers to use the most cost-effective drugs.” But they have done the opposite, fueling higher drug prices through manufacturer rebates and by extorting fees from pharmacy providers.
	6.1 OBSERVATION
Statins Linked to Lower Risk of Early Death in Patients with Colorectal Cancer [Wiley] The meta-analysis included 14 studies involving 130,994 patients with colorectal cancer. Pre-diagnosis statin use was linked with a 15 percent lower risk of dying early from any cause and an 18 percent lower risk of dying from cancer. Post-diagnosis statin use was linked with a 14 percent lower risk of all-cause death and a 21 percent lower risk of cancer-specific death.
	6.6 PUBLICATIONS
Death of the author? AI generated books and the production of scientific knowledge [LSE Impact Blog] Only a small subset of what is in the scientific literature is science, the rest is professional activity with the superficial appearance of science.
	6.7 DMP, BIG DATA & APPLIS
CancerLinQ LLC Collaborating with the International Association for the Study of Lung Cancer [ASCO] “The real-world cancer data that CancerLinQ® collects contributes vital information to the oncology field across cancer types,” said CancerLinQ LLC Chief Executive Officer Cory Wiegert. “This collaboration allows us to work with the IASLC as we analyze CancerLinQ’s data on lung cancer, the most commonly occurring and lethal cancer worldwide.”
	6.7.1 IA/BIOINFORMATIQUE
How to tell whether machine-learning systems are robust enough for the real world [MIT] New method quickly detects instances when neural networks make mistakes they shouldn’t.